<DOC>
	<DOCNO>NCT03080740</DOCNO>
	<brief_summary>Randomized , double blind , positive drug parallel comparison , multi-centre clinical trial ass Efficacy Safety Clindamycin palmitate hydrochloride dispersible tablet treatment bacterial vaginosis</brief_summary>
	<brief_title>The Efficacy Safety Study Clindamycin Palmitate Hydrochloride Dispersible Tablet Treatment Bacterial Vaginosis</brief_title>
	<detailed_description>Treatment group : Clindamycin palmitate hydrochloride dispersible tablet . Control group : Metronidazole Tablet .</detailed_description>
	<mesh_term>Vaginal Diseases</mesh_term>
	<mesh_term>Vaginosis , Bacterial</mesh_term>
	<mesh_term>Clindamycin</mesh_term>
	<mesh_term>Clindamycin palmitate</mesh_term>
	<mesh_term>Clindamycin phosphate</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<criteria>1 . Patients clinically diagnose bacterial vaginosis , meet follow criterion : vaginal Gram stain integration score ( Nugent score ) â‰¥7 point 2 . Female patient age 18 55 year old . 3 . Patients sign Informed Consent Form ( ICF ) . 1 . Patients vulvovaginitis cause infectional reason vaginitis vulvovaginal candidiasis , trichomoniasis vaginitis . 2 . Patients receive systemic vaginal antimicrobial therapy week enrol . 3 . Patients vaginal vulvar disorder could effect evaluation efficacy . 4 . Pregnant lactating patient . 5 . Menopausal woman . Menopause definition : perimenopausal woman stop menstruation year . 6 . Women diabetes . 7 . Dependent alcohol could prohibit study period . 8 . Women liver kidney disfunction , blood disorder , mental illness serious disease . 9 . Women allergic metronidazole , clindamycin . 10 . With poor compliance .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>